Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open Life Science Investing
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026 Life Science Investing
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy Life Science Investing
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 Life Science Investing
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Life Science Investing
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 Life Science Investing
Largest Published Study of Molecular Residual Disease in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions Life Science Investing
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 Life Science Investing
